-+ 0.00%
-+ 0.00%
-+ 0.00%

argenx says Phase 3 ADAPT OCULUS trial shows VYVGART improves ocular myasthenia gravis symptoms

PUBT·04/18/2026 05:00:30
Listen to the news
argenx says Phase 3 ADAPT OCULUS trial shows VYVGART improves ocular myasthenia gravis symptoms
  • argenx outlined new VYVGART and VYVGART Hytrulo data for myasthenia gravis and CIDP scheduled for presentation at American Academy of Neurology Annual Meeting in Chicago on April 18-22, 2026.
  • Phase 3 ADAPT OCULUS results were already generated, showing VYVGART improved symptoms in ocular myasthenia gravis, supporting planned US label-expansion filing.
  • Phase 3 ADAPT SERON updates indicated VYVGART produced rapid, repeatable improvement across harder-to-treat generalized myasthenia gravis subtypes, strengthening case for broader use beyond current antibody-defined population.
  • ADHERE post hoc analysis suggested earlier, first-line VYVGART Hytrulo use in treatment-naïve CIDP could deliver early clinical benefit, addressing an evidence gap that may support uptake.
  • Pipeline disclosures flagged two Phase 3 CIDP studies for empasiprubart, reinforcing strategic focus on expanding neuromuscular franchise beyond VYVGART.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. arGEN-X SE published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604180100PRIMZONEFULLFEED1001176523) on April 18, 2026, and is solely responsible for the information contained therein.